



October 29, 2008

Dear Valued Customer,

We are pleased to inform you that QIAGEN on October 2nd announced the acquisition of the Biosystems business from Biotage AB. This transaction enables a combination of the powerful Pyrosequencing technology for high resolution sequence detection and quantification with the expertise of QIAGEN in sample and assay technologies.


Biotage and QIAGEN believe this is great news for our customers because QIAGEN and Pyrosequencing technology make an excellent fit. We share many customers, and technologies developed by Pyrosequencing, including the recently launched PyroMark™Q24, align extremely well with the current and future QIAGEN systems.

Merging the exceptional development of Pyrosequencing technology over the past 10 years with the leadership of QIAGEN in molecular Sample & Assay Technologies will lead to new integrated and innovative solutions covering the entire process from sample to result. This means major benefits as QIAGEN will now be able to offer you a unique portfolio for epigenetic research and analysis of genetic variations in addition to the current Sample & Assay Technology portfolio.

There will be no immediate changes in contacts or ordering processes and Biosystems' products will continue to be sold through Biotage until the end of the year. For the Pyrosequencing customer, no services will be discontinued as a consequence of this deal. We will of course inform you in advance should there be any change to the format or structure of your customer support or other service.

For further information please visit www.biotagebio.com and www.qiagen.com.

If you have any questions please do not hesitate to contact me or your local sales representative. I would like to thank you for your continued support.



Sincerely,
Torben Jörgensen,
President and CEO

Biotage AB
Kungsgatan 76
SE-753 18 Uppsala, Sweden
Direct: +46 707 49 05 84